Binding of naturally occurring anti-DNA antibodies to estradiol.
March 30, 2021
array, Assay, Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence: supporting the next generation of autophagy researchers and fostering international collaborations., Gerbil, Goat, Guinea Pig, Misrepresentation and distortion of research in biomedical literature., My Blog, profiling, Pure, Purification, purified, Rabbit, Real-time, Recombinant, reverse, RIA, rnai, Translating innovation in biomedical research: Design and delivery of a competency-based regulatory science course.
0 Comments
Binding of naturally occurring human anti-DNA autoantibodies to beta-estradiol and native DNA has been investigated. Sera from seven SLE sufferers had been examined for his or her reactivity with beta-estradiol and native calf thymus DNA. Solid Phase enzyme immunoassay was carried out utilizing each colorigenic and fluorogenic substrates. The outcomes present enhanced binding of human anti-DNA autoantibodies to beta-estradiol as in contrast to native DNA. This was additional substantiated by elevated binding of affinity purified SLE IgG to beta-estradiol. These outcomes recommend a task for feminine intercourse hormone within the etiopathogenesis of SLE and are vital vis-a-vis feminine predominance of SLE.
Structural evaluation of an anti-estradiol antibody.
An anti-estradiol antibody with improved specificity is looked for by combining steroid analog binding research, mutant antibodies obtained from a phage-display library and structural modeling. Three-dimensional fashions for the anti-estradiol antibody 57-2 had been constructed by comparative mannequin constructing. Estradiol and analogs had been docked into the combining website and molecular dynamics simulation was used to additional refine this space of the protein. Cross-reactivities measured in opposition to 36 steroid analogs had been used to assist in the docking course of and to consider the fashions.
The roles of a quantity of residues had been assessed by characterization of cross-reactivity mutants obtained from a phage show library. The cross-reactivity information and the outcomes noticed for mutants are defined by the structural mannequin, wherein the estradiol D-ring inserts deeply into the binding website and interacts with the antibody by at the very least one particular hydrogen bond. The binding information strongly recommend that this hydrogen bond connects the estradiol 17-hydroxyl group with the facet chain of Gln H35. As anticipated for the binding of a small fragrant molecule, the antibody binding website comprises many fragrant residues, e.g. Trp H50, H95 and L96 and Tyr L32, L49 and Phe L91.
Direct colorimetric monoclonal antibody enzyme immunoassay for estradiol-17 beta in saliva.
We developed a direct microtiter plate enzyme immunoassay to measure estradiol-17 beta in saliva. The assay has a commercially obtainable monoclonal antibody, raised in opposition to estradiol-17 beta-6-carboxymethyloximebovine serum albumin, and a homologous horseradish peroxidase conjugate measured colorimetrically. The detection restrict (equal to B0-Three SD) is 365 amol/nicely or 7.Three pmol/L when 50-microL samples are assayed.
Cross-reactivity with estrone and estriol, testosterone, or progesterone is < 0.2%. Estradiol-17 beta was measured in day by day samples over 5 pure menstrual cycles and eight cycles stimulated as a preliminary to in vitro fertilization, and the concentrations and fluctuations discovered agreed with beforehand printed information. This technique offers leads to roughly Three h and could also be helpful for fertility monitoring and administration. IgG subisotype evaluation confirmed IgG2b to be predominant. In abstract, our findings recommend that estrogen, however not dihydrotestosterone, promotes anti-dsDNA antibodies in regular mice.
Retrieval of estradiol receptor in paraffin sections of resting porcine uteri by microwave remedy. Immunostaining patterns obtained with totally different main antibodies.
The unmasking of estradiol receptor in paraffin sections of Bouin’s-fixed uterine tissue from ovariectomized gilts was attained with microwave remedy. Immunocytochemistry of the receptor was carried out utilizing a polyclonal or 5 monoclonal antibodies, two of that are commercially obtainable, reacting with totally different domains of the protein and an amplified-peroxidase system for detection. With 5 of the antibodies, a predominance of nuclear staining was noticed in cells of endometrial glands, whereas one monoclonal antibody (13H2), reacting with the receptor’s area E, confirmed a desire for the cytoplasmic receptor.
In stroma, all antibodies detected extra receptor in nuclei than in cytoplasm. In epithelium, the commercially obtainable antibody H222, our monoclonals 13H2 and HT65, and the polyclonal antibody 402 demonstrated extra receptor in cytoplasmic than in nuclear areas. In myometrium, the nuclei from longitudinal and ring muscle mass had been undoubtedly stained with the antibodies. We conclude that the accessibilities of the antibody epitopes of the receptor differ in accordance to the purposeful uterine cell kind.
17 beta-estradiol, however not 5 alpha-dihydrotestosterone, augments antibodies to double-stranded deoxyribonucleic acid in nonautoimmune C57BL/6J mice.
The affect of intercourse hormones on the immune response to overseas antigens in addition to self-antigens is now acknowledged. In this examine, we investigated the affect of gender and intercourse hormones on the event of antibodies to double-stranded DNA in nonautoimmune C57BL/6J mice. Immunoglobulin G (IgG) anti-dsDNA antibodies are generally current in lupus sufferers and a number of other autoimmune disease-prone murine strains. We discovered that C57BL/6J mice have detectable antibodies (IgM and IgG, however not IgA) to dsDNA. Interestingly, the incidence and degree of IgG anti-dsDNA antibodies had been decrease in male than in feminine mice.
Orchidectomy or administration of 5 alpha-dihydrotestosterone to orchidectomized male mice had minimal results on these antibodies. In distinction, administration of 17 beta-estradiol to orchidectomized or intact males considerably elevated each the incidence and ranges of anti-dsDNA antibodies. In feminine mice, ovariectomy decreased whereas administration of estrogen augmented the incidence and ranges of anti-dsDNA antibodies in ovariectomized in addition to intact feminine mice. Kinetic research revealed that estrogen remedy of female and male mice induced earlier and sustained expression of IgG anti-dsDNA antibodies in contrast to controls.
Investigation of a 17 beta-estradiol-monoclonal antiestradiol antibody binding mechanism utilizing dilute options of natural solvents.
Quantitative understanding of steroid hormone transport and receptor-mediated motion requires data of the bonding forces concerned in every steroid-protein advanced and the consequences of a organic atmosphere on these forces. An method to these issues utilizing dilute options of water-miscible natural solvents, with a variety of polarity, dielectric and hydrogen bonding properties, was examined on an estradiol-antiestradiol antibody binding system on the idea that evaluating the consequences of the solvents would each allow the significance of hydrophobic and hydrogen bonding to be differentiated and provides info on the consequences of the atmosphere on the response. The outcomes had been in contrast with thermodynamic measurements.
All the solvents decreased the Gibbs free power of binding as a perform of their focus within the medium. The decreases had been nearly a monotonic perform of their dielectric fixed, indicating decreased hydrogen bonding. Analysis of the decreases in phrases of the solvents’ hydrogen bonding and polarity properties supported this. Thermodynamic measurement confirmed the binding response was enthalpy-driven with, total, a barely unfavorable entropy contribution. This once more confirmed the hydrophobic impact was not the primary bonding drive.
 Cyclopropyl Hydrazine Hydrochloride |
|||
| abx188669-100g | Abbexa | 100 g | EUR 2054 |
|
|||
hydrazine hydrochloride) (2-Fluorobenzyl)hydrazine hydrochloride |
|||
| abx180090-10g | Abbexa | 10 g | EUR 370 |
|
|||
hydrazine hydrochloride) (4-Methoxybenzyl)hydrazine hydrochloride |
|||
| 20-abx181427 | Abbexa |
|
|
|
|||
 2,3-Dichlorophenyl hydrazine hydrochloride |
|||
| 20-abx181633 | Abbexa |
|
|
|
|||
hydrazine hydrochloride) (3-Nitrophenyl)hydrazine hydrochloride |
|||
| 20-abx184852 | Abbexa |
|
|
|
|||
 4-Fluorphenyl hydrazine hydrochloride |
|||
| 20-abx185223 | Abbexa |
|
|
|
|||
 4-Trifluoromethylphenyl hydrazine hydrochloride |
|||
| 20-abx185244 | Abbexa |
|
|
|
|||
Hydrazine Hydrochloride) (4-Iodophenyl)Hydrazine Hydrochloride |
|||
| abx188013-500g | Abbexa | 500 g | EUR 996 |
|
|||
 4-Bromophenyl hydrazine hydrochloride |
|||
| 20-abx183549 | Abbexa |
|
|
|
|||
hydrazine Hydrochloride) (4-BroMo-3-fluorophenyl)hydrazine Hydrochloride |
|||
| 20-abx182736 | Abbexa |
|
|
|
|||
-, hydrochloride (1:1)) Hydrazine,(2-chloro-4-fluorophenyl)-, hydrochloride (1:1) |
|||
| 20-abx180781 | Abbexa |
|
|
|
|||
-, hydrochloride (1:1)) Hydrazine,(3-chloro-2-fluorophenyl)-, hydrochloride (1:1) |
|||
| 20-abx181296 | Abbexa |
|
|
|
|||
-, hydrochloride (1:1)) Hydrazine,(5-chloro-2-fluorophenyl)-, hydrochloride (1:1) |
|||
| 20-abx182486 | Abbexa |
|
|
|
|||
 Hydrazine monohydrochloride |
|||
| 20-abx184117 | Abbexa |
|
|
|
|||
 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride |
|||
| 20-abx186150 | Abbexa |
|
|
|
|||
hydrazine) (4-Chlorophenyl)hydrazine |
|||
| 20-abx180930 | Abbexa |
|
|
|
|||
hydrazine) (3,4-Dimethylphenyl)hydrazine |
|||
| 20-abx182729 | Abbexa |
|
|
|
|||
phenyl] Isothiourea (hydrochloride)) S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) |
|||
| C5660-10 | ApexBio | 10 mg | EUR 112 |
|
Description: S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) is a selective and competitive nNOS inhibitor with Ki value of 0.32 ?M for the purified human enzyme [1]. |
|||
S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) |
|||
| C5660-100 | ApexBio | 100 mg | EUR 537 |
|
Description: S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) is a selective and competitive nNOS inhibitor with Ki value of 0.32 ?M for the purified human enzyme [1]. |
|||
S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) |
|||
| C5660-25 | ApexBio | 25 mg | EUR 187 |
|
Description: S-ethyl N-[4-(trifluoromethyl)phenyl] Isothiourea (hydrochloride) is a selective and competitive nNOS inhibitor with Ki value of 0.32 ?M for the purified human enzyme [1]. |
|||
Ethyl)Carbamoyl)Phenyl)Boronic Acid Hydrochloride) (4-((2-(Diethylamino)Ethyl)Carbamoyl)Phenyl)Boronic Acid Hydrochloride |
|||
| 20-abx187985 | Abbexa |
|
|
|
|||
hydrazine dihydrochloride) (4-Chlorobenzyl)hydrazine dihydrochloride |
|||
| 20-abx181426 | Abbexa |
|
|
|
|||
Phenyl)(Phenyl)Methanone) (4-(Bromomethyl)Phenyl)(Phenyl)Methanone |
|||
| abx187996-500g | Abbexa | 500 g | EUR 1776 |
|
|||
Carbamoyl)Phenyl)Boronic Acid Hydrochloride) (3-((1H-Tetrazol-5-Yl)Carbamoyl)Phenyl)Boronic Acid Hydrochloride |
|||
| 20-abx187961 | Abbexa |
|
|
|
|||
Carbamoyl)Phenyl)Boronic Acid Hydrochloride) (4-((4-Methylpiperazin-1-Yl)Carbamoyl)Phenyl)Boronic Acid Hydrochloride |
|||
| 20-abx187993 | Abbexa |
|
|
|
|||
-phenyl-amine) (4-tert-Butyl-phenyl)-phenyl-amine |
|||
| 20-abx181430 | Abbexa |
|
|
|
|||
 Phenyl sulfate |
|||
| B6050-25 | ApexBio | 25 mg | EUR 1210 |
Phenyl sulfate |
|||
| B6050-5 | ApexBio | 5 mg | EUR 456 |
 Phenyl Bromoacetate |
|||
| abx188833-1kg | Abbexa | 1 kg | EUR 620 |
|
|||
 Phenyl-benzothiazole |
|||
| B7851-1000 | ApexBio | 1 g | EUR 189 |
hydrazine) (4-Bromo-3-fluorophenyl)hydrazine |
|||
| 20-abx186089 | Abbexa |
|
|
|
|||
hydrazine) N-biotinoyl-N-(maleimidohexanoyl)hydrazine |
|||
| abx187867-1g | Abbexa | 1 g | EUR 1344 |
|
|||
Carbamoyl)Phenyl)Boronic Acid Hydrochloride) (4-((4H-1,2,4-Triazol-4-Yl)Carbamoyl)Phenyl)Boronic Acid Hydrochloride |
|||
| 20-abx187992 | Abbexa |
|
|
|
|||
Phenyl)Carbamoyl)Phenyl)Boronic Acid) (4-((4-(Trifluoromethoxy)Phenyl)Carbamoyl)Phenyl)Boronic Acid |
|||
| 20-abx187990 | Abbexa |
|
|
|
|||
 Cellufine MAX Phenyl |
|||
| 20700 | JNC America | 100 ml | EUR 366 |
Cellufine MAX Phenyl |
|||
| 20701 | JNC America | 500 ml | EUR 995 |
Cellufine MAX Phenyl |
|||
| 20702 | JNC America | 5 lt | Ask for price |
Cellufine MAX Phenyl |
|||
| 20703 | JNC America | 10 lt | Ask for price |
 S-Phenyl Thioacetate |
|||
| 20-abx188887 | Abbexa |
|
|
|
|||
 N-Phenyl isonicotinicamide |
|||
| 20-abx180061 | Abbexa |
|
|
|
|||
 Methyl phenyl sulfone |
|||
| 20-abx181322 | Abbexa |
|
|
|
|||
 Ethyl phenyl sulfide |
|||
| 20-abx184689 | Abbexa |
|
|
|
|||
 Cyclohexyl phenyl ketone |
|||
| 20-abx182405 | Abbexa |
|
|
|
|||
 Phenyl-benzothiazole HCl |
|||
| A8770-1000 | ApexBio | 1 g | EUR 189 |
 Phenyl isothiocyanate, 99% |
|||
| GX7854-5ML | Glentham Life Sciences | 5 ml | EUR 118 |
hydrazine dihydrochloride) (Tetrahydro-2H-pyran-4-yl)hydrazine dihydrochloride |
|||
| 20-abx180120 | Abbexa |
|
|
|
|||
hydrazine, HCl) 1-(2-BroMo-4-Methylphenyl)hydrazine, HCl |
|||
| 20-abx182804 | Abbexa |
|
|
|
|||
 Cellufine MAX Phenyl LS |
|||
| 20800 | JNC America | 100 ml | EUR 366 |
Cellufine MAX Phenyl LS |
|||
| 20801 | JNC America | 500 ml | EUR 995 |
Cellufine MAX Phenyl LS |
|||
| 20802 | JNC America | 5 lt | Ask for price |
Cellufine MAX Phenyl LS |
|||
| 20803 | JNC America | 10 lt | Ask for price |
 MC Cellufine MAX Phenyl |
|||
| 20-700-51 | JNC America | 5 x 1 ml | EUR 271 |
MC Cellufine MAX Phenyl |
|||
| 20-700-55 | JNC America | 5 x 5 ml | EUR 537 |
-OH) H-Cys(phenyl)-OH |
|||
| E-3400.0001 | Bachem | 1.0g | EUR 176 |
|
Description: Sum Formula: C9H11NO2S; CAS# [34317-61-8] |
|||
H-Cys(phenyl)-OH |
|||
| E-3400.0005 | Bachem | 5.0g | EUR 587 |
|
Description: Sum Formula: C9H11NO2S; CAS# [34317-61-8] |
|||
 Boc-Glu-phenyl ester |
|||
| A-4540.0001 | Bachem | 1.0g | EUR 151 |
|
Description: Sum Formula: C16H21NO6; CAS# [59587-94-9] |
|||
Boc-Glu-phenyl ester |
|||
| A-4540.0005 | Bachem | 5.0g | EUR 526 |
|
Description: Sum Formula: C16H21NO6; CAS# [59587-94-9] |
|||
Phenyl Isothiocyanate) 4-(Trifluoromethoxy)Phenyl Isothiocyanate |
|||
| abx188418-50g | Abbexa | 50 g | EUR 523 |
|
|||
 1-Phenyl-1,2-propanedione |
|||
| 20-abx180022 | Abbexa |
|
|
|
|||
Phenyl Isocyanate) 4-(Maleinimido)Phenyl Isocyanate |
|||
| abx180470-1g | Abbexa | 1 g | EUR 2012 |
|
|||
 N-phenyl-2-naphthylamine |
|||
| 20-abx181333 | Abbexa |
|
|
|
|||
 5-Phenyl-1H-tetrazole |
|||
| abx184628-500g | Abbexa | 500 g | EUR 314 |
|
|||
 2-Phenyl-1,3-Dioxolane |
|||
| 20-abx185083 | Abbexa |
|
|
|
|||
Acetamide) Phenyl-(2-Pyridyl)Acetamide |
|||
| 20-abx185536 | Abbexa |
|
|
|
|||
 2-Phenyl-2-Propanol |
|||
| 20-abx186243 | Abbexa |
|
|
|
|||
 4-phenyl-1,2,3-Thiadiazole |
|||
| C4691-1000 | ApexBio | 1 g | EUR 135 |
4-phenyl-1,2,3-Thiadiazole |
|||
| C4691-5000 | ApexBio | 5 g | EUR 428 |
) N-Phenyl-bis(trifluoromethanesulfonimide) |
|||
| GX3512-5G | Glentham Life Sciences | 5 g | EUR 70 |
 Phenyl b-D-thioglucopyranoside |
|||
| GC0722-100MG | Glentham Life Sciences | 100 mg | EUR 94 |
Phenyl b-D-thioglucopyranoside |
|||
| GC0722-1G | Glentham Life Sciences | 1 g | EUR 341 |
Phenyl b-D-thioglucopyranoside |
|||
| GC0722-250MG | Glentham Life Sciences | 250 mg | EUR 150 |
Phenyl b-D-thioglucopyranoside |
|||
| GC0722-500MG | Glentham Life Sciences | 500 mg | EUR 205 |
Phenyl b-D-thioglucopyranoside |
|||
| GC0722-50MG | Glentham Life Sciences | 50 mg | EUR 70 |
 Phenyl b-D-glucopyranoside |
|||
| GC6682-25G | Glentham Life Sciences | 25 g | EUR 229 |
Phenyl b-D-glucopyranoside |
|||
| GC6682-5G | Glentham Life Sciences | 5 g | EUR 86 |
phenyl isothiocyanate) 4-(Trifluoromethyl)phenyl isothiocyanate |
|||
| GK7826-5G | Glentham Life Sciences | 5 g | EUR 109 |
 MC Cellufine MAX Phenyl LS |
|||
| 20-800-51 | JNC America | 5 x 1 ml | EUR 271 |
MC Cellufine MAX Phenyl LS |
|||
| 20-800-55 | JNC America | 5 x 5 ml | EUR 537 |
 Fmoc-4-phenyl-Phe-OH |
|||
| B-3155.0001 | Bachem | 1.0g | EUR 418 |
|
Description: Sum Formula: C30H25NO4; CAS# [199110-64-0] |
|||
Fmoc-4-phenyl-Phe-OH |
|||
| B-3155.0005 | Bachem | 5.0g | EUR 1554 |
|
Description: Sum Formula: C30H25NO4; CAS# [199110-64-0] |
|||
 Boc-4-phenyl-Phe-OH |
|||
| A-4385.0001 | Bachem | 1.0g | EUR 490 |
|
Description: Sum Formula: C20H23NO4; CAS# [147923-08-8] |
|||
Boc-4-phenyl-Phe-OH |
|||
| A-4385.0005 | Bachem | 5.0g | EUR 1844 |
|
Description: Sum Formula: C20H23NO4; CAS# [147923-08-8] |
|||
-Aceticacid) Amino-(2-Chloro-Phenyl)-Aceticacid |
|||
| abx188588-5000g | Abbexa | 5000 g | EUR 773 |
|
|||
phenyl propanal) 3-(4-Carboethoxy)phenyl propanal |
|||
| 20-abx180030 | Abbexa |
|
|
|
|||
-Acetamidine) 2-(2-Chloro-Phenyl)-Acetamidine |
|||
| 20-abx180204 | Abbexa |
|
|
|
|||
phenyl)ethanone) 1-(4-(Difluoromethoxy)phenyl)ethanone |
|||
| 20-abx180943 | Abbexa |
|
|
|
|||
phenyl)methanol) (4-(tert-Butyl)phenyl)methanol |
|||
| 20-abx181420 | Abbexa |
|
|
|
|||
phenyl]propanoicacid) 3-[4-(trifluoromethoxy)phenyl]propanoicacid |
|||
| 20-abx181879 | Abbexa |
|
|
|
|||
 4-Chloro-2-phenyl-pyrimidine |
|||
| 20-abx182082 | Abbexa |
|
|
|
|||
-ethylamine) 2-(3-Fluoro-phenyl)-ethylamine |
|||
| 20-abx185696 | Abbexa |
|
|
|
|||
-ethylamine) 2-(4-Chloro-phenyl)-ethylamine |
|||
| 20-abx185697 | Abbexa |
|
|
|
|||
-ethylamine) 2-(4-Methoxy-phenyl)-ethylamine |
|||
| 20-abx185698 | Abbexa |
|
|
|
|||
-Oxo-Acetonitrile) (2-Chloro-Phenyl)-Oxo-Acetonitrile |
|||
| 20-abx186083 | Abbexa |
|
|
|
|||
-Methanesulfonyl Chloride) (2-Fluoro-Phenyl)-Methanesulfonyl Chloride |
|||
| abx187958-1g | Abbexa | 1 g | EUR 370 |
|
|||
Phenyl]Boronic Acid) [4-(Methoxycarbamoyl)Phenyl]Boronic Acid |
|||
| 20-abx188057 | Abbexa |
|
|
|
|||
Phenyl Boronic Acid) 2-(Aminomethyl)Phenyl Boronic Acid |
|||
| abx188153-1g | Abbexa | 1 g | EUR 1080 |
|
|||
Phenyl]-Boronic Acid) [3-(Dimethylamino)Phenyl]-Boronic Acid |
|||
| 20-abx182795 | Abbexa |
|
|
|
|||
Phenyl]Boronic Acid) [3-(Methylcarbamoyl)Phenyl]Boronic Acid |
|||
| 20-abx182796 | Abbexa |
|
|
|
|||
Phenyl]Boronic Acid) [4-(Morpholinomethyl)Phenyl]Boronic Acid |
|||
| 20-abx182798 | Abbexa |
|
|
|
|||
Phenyl]Boronic Acid) [4-(Phenylcarbonyl)Phenyl]Boronic Acid |
|||
| 20-abx182799 | Abbexa |
|
|
|
|||
-ethylamine) 2-(3-Bromo-phenyl)-ethylamine |
|||
| 20-abx182924 | Abbexa |
|
|
|
|||
-pyrrolidine) 2-(4-Chloro-phenyl)-pyrrolidine |
|||
| 20-abx182926 | Abbexa |
|
|
|
|||
 H-4-Phenyl-Phe-OH |
|||
| F-3645.0001 | Bachem | 1.0g | EUR 418 |
|
Description: Sum Formula: C15H15NO2; CAS# [155760-02-4] |
|||
H-4-Phenyl-Phe-OH |
|||
| F-3645.0005 | Bachem | 5.0g | EUR 1554 |
|
Description: Sum Formula: C15H15NO2; CAS# [155760-02-4] |
|||
 Phenyl phosphate disodium salt dihydrate |
|||
| GE1672-100G | Glentham Life Sciences | 100 g | EUR 150 |
Phenyl phosphate disodium salt dihydrate |
|||
| GE1672-10G | Glentham Life Sciences | 10 g | EUR 52 |
Phenyl phosphate disodium salt dihydrate |
|||
| GE1672-25G | Glentham Life Sciences | 25 g | EUR 74 |
Phenyl phosphate disodium salt dihydrate |
|||
| GE1672-50G | Glentham Life Sciences | 50 g | EUR 99 |
-(+)-4-Phenyl-2-oxazolidinone) (S)-(+)-4-Phenyl-2-oxazolidinone |
|||
| GK1601-100G | Glentham Life Sciences | 100 g | EUR 181 |
(S)-(+)-4-Phenyl-2-oxazolidinone |
|||
| GK1601-25G | Glentham Life Sciences | 25 g | EUR 94 |
 NuGel™ Phenyl Boronic Acid |
|||
| NPBA-05 | Biotech Support Group | 5g | EUR 679 |
|
Description: Glycoprotein Enrichment kit |
|||
NuGel™ Phenyl Boronic Acid |
|||
| NPBA-10 | Biotech Support Group | 10g | EUR 953 |
|
Description: Glycoprotein Enrichment kit |
|||
 Purified GFP |
|||
| AG45-0205-Z | Immunology Consultants Laboratory | 0.1 mg | EUR 228 |
 Ovalbumin, purified |
|||
| O705084 | Bio Basic | 1g | EUR 67.4 |
|
|||
 Fmoc-4-phenyl-D-Phe-OH |
|||
| B-3160.0001 | Bachem | 1.0g | EUR 660 |
|
Description: Sum Formula: C30H25NO4; CAS# [205526-38-1] |
|||
Fmoc-4-phenyl-D-Phe-OH |
|||
| B-3160.0005 | Bachem | 5.0g | EUR 2533 |
|
Description: Sum Formula: C30H25NO4; CAS# [205526-38-1] |
|||
 Boc-4-phenyl-D-Phe-OH |
|||
| A-4390.0001 | Bachem | 1.0g | EUR 599 |
|
Description: Sum Formula: C20H23NO4; CAS# [128779-47-5] |
|||
Boc-4-phenyl-D-Phe-OH |
|||
| A-4390.0005 | Bachem | 5.0g | EUR 2316 |
|
Description: Sum Formula: C20H23NO4; CAS# [128779-47-5] |
|||
 H-4-Phenyl-L-Phe-Oh |
|||
| 20-abx188725 | Abbexa |
|
|
|
|||
 2-Phenyl-imidazo[1,2-a]pyridine |
|||
| 20-abx180360 | Abbexa |
|
|
|
|||
-alpha-Bromo-alpha-phenyl acetonitrile) (S)-alpha-Bromo-alpha-phenyl acetonitrile |
|||
| 20-abx181469 | Abbexa |
|
|
|
|||
 3-Phenyl-1H-pyrazole-4-carbaldehyde |
|||
| 20-abx181988 | Abbexa |
|
|
|
|||
sulfonyl]phenyl}boronic acid) {4-[(dimethylamino)sulfonyl]phenyl}boronic acid |
|||
| 20-abx184894 | Abbexa |
|
|
|
|||
Phenyl-4-Carboxyquinoline) 2-(4-Dihydroxyborane)Phenyl-4-Carboxyquinoline |
|||
| 20-abx185622 | Abbexa |
|
|
|
|||
 4-Bromo-1-phenyl-1H-pyrazole |
|||
| 20-abx185942 | Abbexa |
|
|
|
|||
Phenyl]Boronic Acid) [3-(3-Pyridinylcarbamoyl)Phenyl]Boronic Acid |
|||
| 20-abx188049 | Abbexa |
|
|
|
|||
Phenyl]Boronic Acid) [4-(3-Pentanylcarbamoyl)Phenyl]Boronic Acid |
|||
| 20-abx188055 | Abbexa |
|
|
|
|||
-1,2-Oxaziridine) 3-Phenyl-2-(Phenylsulfonyl)-1,2-Oxaziridine |
|||
| abx188398-1g | Abbexa | 1 g | EUR 342 |
|
|||
 H-4-Phenyl-D-Phe-OH |
|||
| 20-abx184102 | Abbexa |
|
|
|
|||
propane) 2-Phenyl-2-(1-piperidinyl)propane |
|||
| C5047-10 | ApexBio | 10 mg | EUR 440 |
|
Description: KI: 11 microM for 7-(benzyloxy)resorufin O-dealkylation activity of liver microsomes obtained from phenobarbital-induced rats 2-Phenyl-2-(1-piperidinyl)propane is a mechanism-based inactivator of human cytochrome P450 (CYP) 2B6. |
|||
2-Phenyl-2-(1-piperidinyl)propane |
|||
| C5047-25 | ApexBio | 25 mg | EUR 902 |
|
Description: KI: 11 microM for 7-(benzyloxy)resorufin O-dealkylation activity of liver microsomes obtained from phenobarbital-induced rats 2-Phenyl-2-(1-piperidinyl)propane is a mechanism-based inactivator of human cytochrome P450 (CYP) 2B6. |
|||
2-Phenyl-2-(1-piperidinyl)propane |
|||
| C5047-5 | ApexBio | 5 mg | EUR 257 |
|
Description: KI: 11 microM for 7-(benzyloxy)resorufin O-dealkylation activity of liver microsomes obtained from phenobarbital-induced rats 2-Phenyl-2-(1-piperidinyl)propane is a mechanism-based inactivator of human cytochrome P450 (CYP) 2B6. |
|||
 4-phenyl-5-methyl-1,2,3-Thiadiazole |
|||
| C4429-1000 | ApexBio | 1 g | EUR 100 |
|
Description: 4-phenyl-5-methyl-1,2,3-Thiadiazole is a CYP2B4 and CYP2E1 inhibitor. |
|||
4-phenyl-5-methyl-1,2,3-Thiadiazole |
|||
| C4429-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 113 |
|
Description: 4-phenyl-5-methyl-1,2,3-Thiadiazole is a CYP2B4 and CYP2E1 inhibitor. |
|||
4-phenyl-5-methyl-1,2,3-Thiadiazole |
|||
| C4429-5000 | ApexBio | 5 g | EUR 274 |
|
Description: 4-phenyl-5-methyl-1,2,3-Thiadiazole is a CYP2B4 and CYP2E1 inhibitor. |
|||
 3-bromo-5-phenyl Salicylic Acid |
|||
| C4516-1 | ApexBio | 1 mg | EUR 121 |
|
Description: Ki: 140 nM for AKR1C1; 1.97 ?M for AKR1C2; 21 ?M for AKR1C3 3-bromo-5-phenyl Salicylic acid is an AKR1C1 inhibitor. |
|||
3-bromo-5-phenyl Salicylic Acid |
|||
| C4516-10 | ApexBio | 10 mg | EUR 618 |
|
Description: Ki: 140 nM for AKR1C1; 1.97 ?M for AKR1C2; 21 ?M for AKR1C3 3-bromo-5-phenyl Salicylic acid is an AKR1C1 inhibitor. |
|||
3-bromo-5-phenyl Salicylic Acid |
|||
| C4516-25 | ApexBio | 25 mg | EUR 1292 |
|
Description: Ki: 140 nM for AKR1C1; 1.97 ?M for AKR1C2; 21 ?M for AKR1C3 3-bromo-5-phenyl Salicylic acid is an AKR1C1 inhibitor. |
|||
3-bromo-5-phenyl Salicylic Acid |
|||
| C4516-5 | ApexBio | 5 mg | EUR 370 |
|
Description: Ki: 140 nM for AKR1C1; 1.97 ?M for AKR1C2; 21 ?M for AKR1C3 3-bromo-5-phenyl Salicylic acid is an AKR1C1 inhibitor. |
|||
 5-bromo-3-phenyl Salicylic Acid |
|||
| C4610-1 | ApexBio | 1 mg | EUR 109 |
5-bromo-3-phenyl Salicylic Acid |
|||
| C4610-10 | ApexBio | 10 mg | EUR 528 |
5-bromo-3-phenyl Salicylic Acid |
|||
| C4610-25 | ApexBio | 25 mg | EUR 1098 |
The most deleterious solvent, iso-propanol, not solely decreased the enthalpic contribution to binding however rendered the entropic contribution extra favorable. This method nonetheless doesn’t enable the relative significance of hydrogen bonding and van der Waals contacts within the precise binding to be differentiated but it surely does give indications on how a organic atmosphere could have an effect on a steroid-protein binding response in vivo.
Translating innovation in biomedical research: Design and delivery of a competency-based regulatory science course.
E
Misrepresentation and distortion of research in biomedical literature.
About Author
